Cargando…

Effects of canagliflozin and metformin on insulin resistance and visceral adipose tissue in people with newly-diagnosed type 2 diabetes

BACKGROUND: The current study was to evaluate the effects of canagliflozin and metformin on insulin resistance and visceral adipose tissue in people with newly-diagnosed type 2 diabetes. METHODS: This is an open-label, parallel and controlled study. Participants were divided into canagliflozin (100 ...

Descripción completa

Detalles Bibliográficos
Autores principales: Hao, Zirui, Sun, Yue, Li, Guiping, Shen, Yuli, Wen, Yingzhen, Liu, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8830023/
https://www.ncbi.nlm.nih.gov/pubmed/35144596
http://dx.doi.org/10.1186/s12902-022-00949-0
_version_ 1784648191300337664
author Hao, Zirui
Sun, Yue
Li, Guiping
Shen, Yuli
Wen, Yingzhen
Liu, Yan
author_facet Hao, Zirui
Sun, Yue
Li, Guiping
Shen, Yuli
Wen, Yingzhen
Liu, Yan
author_sort Hao, Zirui
collection PubMed
description BACKGROUND: The current study was to evaluate the effects of canagliflozin and metformin on insulin resistance and visceral adipose tissue in people with newly-diagnosed type 2 diabetes. METHODS: This is an open-label, parallel and controlled study. Participants were divided into canagliflozin (100 mg/qd) or metformin (1000 mg/bid) groups. At baseline and after 12 weeks’ therapy, insulin resistance [Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)], subcutaneous and visceral adipose tissue, fasting blood glucose (FBG), glycated hemoglobin A1c (HbA1c), C-reactive protein (CRP) and nitric oxide (NO) were evaluated and compared. RESULTS: There was no significant between-group difference in baseline characteristics. After 12 weeks’ therapy, in canagliflozin group (n = 67), compared to baseline, FBG, HbA1c and HOMA-IR were decreased, accompanying with reduction of visceral adipose tissue. Compared to metformin group (n = 73), FBG, HbA1c and HOMA-IR were lower in canagliflozin group, accompanying with less visceral adipose tissue and lower serum CRP level and higher NO level. After multivariable regression analysis, age, visceral adipose tissue and CRP remained associated with increased insulin resistance, while canagliflozin treatment and higher NO level were associated with reduced insulin resistance. Body mass index, waist/hip ratio, CRP and HOMA-IR remained associated with increased visceral adipose tissue, while canagliflozin treatment and higher NO level were associated with reduced visceral adipose tissue. There was no difference in adverse event between these two groups. CONCLUSION: Canagliflozin reduces visceral adipose tissue and improves blood glucose, insulin resistance and systemic inflammation in people with newly-diagnosed type 2 diabetes.
format Online
Article
Text
id pubmed-8830023
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-88300232022-02-11 Effects of canagliflozin and metformin on insulin resistance and visceral adipose tissue in people with newly-diagnosed type 2 diabetes Hao, Zirui Sun, Yue Li, Guiping Shen, Yuli Wen, Yingzhen Liu, Yan BMC Endocr Disord Research BACKGROUND: The current study was to evaluate the effects of canagliflozin and metformin on insulin resistance and visceral adipose tissue in people with newly-diagnosed type 2 diabetes. METHODS: This is an open-label, parallel and controlled study. Participants were divided into canagliflozin (100 mg/qd) or metformin (1000 mg/bid) groups. At baseline and after 12 weeks’ therapy, insulin resistance [Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)], subcutaneous and visceral adipose tissue, fasting blood glucose (FBG), glycated hemoglobin A1c (HbA1c), C-reactive protein (CRP) and nitric oxide (NO) were evaluated and compared. RESULTS: There was no significant between-group difference in baseline characteristics. After 12 weeks’ therapy, in canagliflozin group (n = 67), compared to baseline, FBG, HbA1c and HOMA-IR were decreased, accompanying with reduction of visceral adipose tissue. Compared to metformin group (n = 73), FBG, HbA1c and HOMA-IR were lower in canagliflozin group, accompanying with less visceral adipose tissue and lower serum CRP level and higher NO level. After multivariable regression analysis, age, visceral adipose tissue and CRP remained associated with increased insulin resistance, while canagliflozin treatment and higher NO level were associated with reduced insulin resistance. Body mass index, waist/hip ratio, CRP and HOMA-IR remained associated with increased visceral adipose tissue, while canagliflozin treatment and higher NO level were associated with reduced visceral adipose tissue. There was no difference in adverse event between these two groups. CONCLUSION: Canagliflozin reduces visceral adipose tissue and improves blood glucose, insulin resistance and systemic inflammation in people with newly-diagnosed type 2 diabetes. BioMed Central 2022-02-10 /pmc/articles/PMC8830023/ /pubmed/35144596 http://dx.doi.org/10.1186/s12902-022-00949-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Hao, Zirui
Sun, Yue
Li, Guiping
Shen, Yuli
Wen, Yingzhen
Liu, Yan
Effects of canagliflozin and metformin on insulin resistance and visceral adipose tissue in people with newly-diagnosed type 2 diabetes
title Effects of canagliflozin and metformin on insulin resistance and visceral adipose tissue in people with newly-diagnosed type 2 diabetes
title_full Effects of canagliflozin and metformin on insulin resistance and visceral adipose tissue in people with newly-diagnosed type 2 diabetes
title_fullStr Effects of canagliflozin and metformin on insulin resistance and visceral adipose tissue in people with newly-diagnosed type 2 diabetes
title_full_unstemmed Effects of canagliflozin and metformin on insulin resistance and visceral adipose tissue in people with newly-diagnosed type 2 diabetes
title_short Effects of canagliflozin and metformin on insulin resistance and visceral adipose tissue in people with newly-diagnosed type 2 diabetes
title_sort effects of canagliflozin and metformin on insulin resistance and visceral adipose tissue in people with newly-diagnosed type 2 diabetes
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8830023/
https://www.ncbi.nlm.nih.gov/pubmed/35144596
http://dx.doi.org/10.1186/s12902-022-00949-0
work_keys_str_mv AT haozirui effectsofcanagliflozinandmetforminoninsulinresistanceandvisceraladiposetissueinpeoplewithnewlydiagnosedtype2diabetes
AT sunyue effectsofcanagliflozinandmetforminoninsulinresistanceandvisceraladiposetissueinpeoplewithnewlydiagnosedtype2diabetes
AT liguiping effectsofcanagliflozinandmetforminoninsulinresistanceandvisceraladiposetissueinpeoplewithnewlydiagnosedtype2diabetes
AT shenyuli effectsofcanagliflozinandmetforminoninsulinresistanceandvisceraladiposetissueinpeoplewithnewlydiagnosedtype2diabetes
AT wenyingzhen effectsofcanagliflozinandmetforminoninsulinresistanceandvisceraladiposetissueinpeoplewithnewlydiagnosedtype2diabetes
AT liuyan effectsofcanagliflozinandmetforminoninsulinresistanceandvisceraladiposetissueinpeoplewithnewlydiagnosedtype2diabetes